4.34

5.86% -0.27

After Hours: 4.39 0.05 +1.15%

Trisalus Life Sciences Inc (TLSI)

Overview News Price History Discussions Forecast

Trisalus Life Sciences Inc stock is traded at $4.34, with a volume of 348.07K. It is down -5.86% in the last 24 hours and down -13.72% over the past month. TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Previous Close:

$4.61

Open:

$4.57

24h Volume:

348.07K

Relative Volume:

1.06

Market Cap:

$267.23M

Revenue:

$45.15M

Net Income/Loss:

$-39.23M

P/E Ratio:

-2.3729

EPS:

-1.829

Net Cash Flow:

$-18.93M

1W Performance:

-14.90%

1M Performance:

-13.72%

6M Performance:

+8.23%

1Y Performance:

-8.82%

1-Day Range:

$4.32

$4.62

1-Week Range:

$4.32

$5.83

52-Week Range:

$2.20

$7.95

Trisalus Life Sciences Inc Stock (TLSI) Company Profile

Name

Trisalus Life Sciences Inc

Sector

Healthcare (1067)

Industry

Medical Devices (139)

Phone

415 336 8917

Address

6272 WEST 91ST AVENUE, WESTMINSTER

Employee

102

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

TLSI's Discussions on Twitter

Compare TLSI vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TLSI Trisalus Life Sciences Inc	4.34	267.23M	45.15M	-39.23M	-18.93M	-1.829
ABT Abbott Laboratories	101.29	175.27B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	88.64	113.38B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	272.36	104.47B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	43.92	63.65B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.29	49.74B	6.30B	1.07B	1.09B	1.8406

Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
Nov-11-24	Initiated	ROTH MKM	Buy
Oct-25-24	Initiated	Northland Capital	Outperform
Sep-16-24	Initiated	Oppenheimer	Outperform
May-30-24	Initiated	Canaccord Genuity	Buy

View All

Trisalus Life Sciences Inc Stock (TLSI) Latest News

Sep 25, 2026

FDA Clears TriNav Advance for Expanded Liver Embolization Access - CancerNetwork

Sep 25, 2026

Sep 23, 2026

TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance - marketscreener.com

Sep 23, 2026

TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support - TradingView

Sep 23, 2026

TriSalus Life Sciences Price Target Raised to $12.00/Share From $11.00 by HC Wainwright & Co. - Moomoo

Sep 23, 2026

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga

Sep 23, 2026

TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance - Yahoo Finance

Sep 23, 2026

H.C. Wainwright raises TriSalus stock price target on FDA approval By Investing.com - Investing.com Australia

Sep 23, 2026

H.C. Wainwright raises TriSalus stock price target on FDA approval - Investing.com

Sep 23, 2026

TLSI Looks 31.8% Overvalued on GF Value™ After FDA Nod for TriNa - GuruFocus

Sep 23, 2026

HC Wainwright & Co. maintains Buy rating on TriSalus Life Sciences, $12 price target - TradingView

Sep 23, 2026

Why is TriSalus Life Sciences stock surging today? By Investing.com - Investing.com Canada

Sep 23, 2026

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization - BioSpace

Sep 23, 2026

Sep 22, 2026

TriSalus Life shares surge 29% on FDA device clearance By Investing.com - Investing.com South Africa

Sep 22, 2026

Trisalus Life Sciences Receives FDA Clearance For Trinav Advance - TradingView

Sep 22, 2026

TriSalus receives FDA clearance for TriNav Advance device By Investing.com - Investing.com Australia

Sep 22, 2026

TriSalus Gains FDA Clearance for TriNav Advance Device - TipRanks

Sep 22, 2026

TriSalus receives FDA clearance for TriNav Advance device - Investing.com

Sep 22, 2026

Sep 14, 2026

TLSI: Innovative tumor therapy delivery, rapid growth, and new product launches drive future outlook - TradingView

Sep 14, 2026

TriSalus Life Sciences, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (TLSI) - Traders Union

Sep 14, 2026

Sep 09, 2026

This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Sep 09, 2026

Sep 02, 2026

TriSalus Life Sciences (TLSI) Climbs 1.55% as Support Holds Above $4.99Wyckoff Distribution - vinanet.vn

Sep 02, 2026

Aug 31, 2026

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference - Business Wire

Aug 31, 2026

Aug 30, 2026

TriSalus Life Sciences (TLSI) Slips 2% as Shares Test Key $4.59 Support LevelKey Reversal Day - dars.gov.et

Aug 30, 2026

Aug 25, 2026

TriSalus (TLSI) Results Review: The Bottom-Line Figure Trails Its Comparison in the Available Record; Share Response: Shares Move 3.04% Lower in the Latest SessionWeak Earnings Momentum - vinanet.vn

Aug 25, 2026

Aug 24, 2026

TriSalus (TLSI) Market: Falls 2.18% to $5.16 on the Day; Technical Setup: the Near-Term Reference Band Stretches From $4.90 to $5.42 on the DayETF NAV Deviation - vinanet.vn

Aug 24, 2026

TriSalus (TLSI) Latest: Finishes 1.90% Lower at $5.17 at the Close; Next Test: the Near-Term Reference Band Stretches From $4.91 to $5.43Arms Index - dars.gov.et

Aug 24, 2026

Aug 22, 2026